Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4
ByAinvest
Thursday, Sep 4, 2025 8:18 am ET1min read
CHRS--
Coherus Oncology, a fully integrated commercial-stage innovative oncology company, announced its participation in three upcoming investor conferences in September and October 2025. The company will present at the Baird 2025 Global Healthcare Conference on September 9, the H.C. Wainwright Global Investment Conference on September 10, and the UBS Virtual Oncology Day on October 1, 2025. All presentations will be accessible through webcast links on the company's investor relations website, with replays available for 30 days [1].
The stock price of Coherus BioSciences has shown significant growth, rising by 5.88% on Wednesday, September 3, 2025, from $1.19 to $1.26. The stock has gained 43.13% since August 11, 2025, and has been on a strong upward trend, with positive technical signals from Moving Averages and MACD [2].
Maxim Group's upgrade reflects the company's strong fundamentals, including its approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a promising pipeline of proprietary candidates targeting various cancers. The company's strategy to grow sales of LOQTORZI and advance the development of new indications is expected to drive sales multiples and synergies from proprietary combinations [1].
Investors interested in Coherus Oncology's upcoming presentations or one-on-one meetings with management should contact their respective bank representatives. For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, visit the Coherus website [1].
References:
[1] https://www.stocktitan.net/news/CHRS/coherus-oncology-to-participate-in-upcoming-investor-tj4ax1swcqgp.html
[2] https://stockinvest.us/stock/CHRS
Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4
Maxim Group has upgraded its rating for Coherus Oncology (NASDAQ: CHRS) to "Buy" and set a price target (PT) of $4.00. The upgrade comes amidst positive developments for the company, including its participation in upcoming investor conferences and recent stock price appreciation [1].Coherus Oncology, a fully integrated commercial-stage innovative oncology company, announced its participation in three upcoming investor conferences in September and October 2025. The company will present at the Baird 2025 Global Healthcare Conference on September 9, the H.C. Wainwright Global Investment Conference on September 10, and the UBS Virtual Oncology Day on October 1, 2025. All presentations will be accessible through webcast links on the company's investor relations website, with replays available for 30 days [1].
The stock price of Coherus BioSciences has shown significant growth, rising by 5.88% on Wednesday, September 3, 2025, from $1.19 to $1.26. The stock has gained 43.13% since August 11, 2025, and has been on a strong upward trend, with positive technical signals from Moving Averages and MACD [2].
Maxim Group's upgrade reflects the company's strong fundamentals, including its approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a promising pipeline of proprietary candidates targeting various cancers. The company's strategy to grow sales of LOQTORZI and advance the development of new indications is expected to drive sales multiples and synergies from proprietary combinations [1].
Investors interested in Coherus Oncology's upcoming presentations or one-on-one meetings with management should contact their respective bank representatives. For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, visit the Coherus website [1].
References:
[1] https://www.stocktitan.net/news/CHRS/coherus-oncology-to-participate-in-upcoming-investor-tj4ax1swcqgp.html
[2] https://stockinvest.us/stock/CHRS
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet